{"id":40069,"date":"2025-09-26T11:36:29","date_gmt":"2025-09-26T06:36:29","guid":{"rendered":"https:\/\/menamedicalresearch.com\/news\/?p=40069"},"modified":"2025-09-26T11:36:29","modified_gmt":"2025-09-26T06:36:29","slug":"molecular-profiling-and-targeted-therapy-for-non-small-cell-lung-cancer-in-the-mena-region","status":"publish","type":"post","link":"https:\/\/menamedicalresearch.com\/news\/cancers\/molecular-profiling-and-targeted-therapy-for-non-small-cell-lung-cancer-in-the-mena-region\/","title":{"rendered":"Molecular Profiling and Targeted Therapy for Non-Small Cell Lung Cancer in the MENA Region"},"content":{"rendered":"

The treatment paradigm for advanced non-small cell lung cancer (NSCLC) has been fundamentally changed by the introduction of targeted therapies and immunotherapy<\/strong> over the past decade. Given that lung cancer remains a leading cause of global cancer mortality, understanding the regional molecular epidemiology is vital.<\/p>\n

This systematic review and expert opinion study aimed to determine the prevalence of key oncogenic mutations (ALK, EGFR, KRAS, ROS1, MET, BRAF, and HER2<\/strong>) in NSCLC patients across the Middle East and North Africa (MENA<\/strong>) region and evaluate current treatment approaches in the Gulf Cooperation Council (GCC<\/strong>). The study involved a systematic literature search, complemented by interviews with 10 medical oncologists from the GCC to provide real-world clinical context.<\/p>\n

Analysis of the pooled data revealed significant molecular patterns, underscoring the difference in mutation profiles compared to other global populations. EGFR<\/strong> mutations were found to be the most frequent driver in the MENA region, with a prevalence of 24%<\/strong> (95% CI, 22.05-25.41%), followed by KRAS<\/strong> mutations at 19.7%<\/strong> (95% CI, 15.29-24.07%). The prevalence rates for other mutations were ALK<\/strong> at 7.9%<\/strong>, MET<\/strong> at 4.7%<\/strong>, and BRAF<\/strong> at 3.7%<\/strong>, with ROS1<\/strong> at 2.2%<\/strong>. Data for HER2 mutations were not available.<\/p>\n

Experts noted that while targeted therapies and treatment protocols in GCC countries generally align with major international guidelines (NCCN, ESMO) and are well-funded by governmental healthcare systems, significant challenges remain. These primarily revolve around the standardization and implementation of comprehensive molecular diagnostics, such as Next-Generation Sequencing (NGS) and liquid biopsy, across the region.<\/p>\n

The study concludes that ongoing research is essential to fully characterize driver mutations across the wider MENA countries to further refine and inform future personalized treatment strategies.<\/p>\n

Reference Source
\n<\/strong>AlJassim A, Kanbour A, Azribi F, et al. Prevalence of molecular mutations in non-small cell lung cancer and current treatment approaches in the MENA region: systematic review and expert opinion.
\nJ Immunother Precis Oncol<\/em>. Aug 26, 2025; 8:233-241. DOI: 10.36401\/\u041f\u0420\u041e-24-35.<\/p>\n","protected":false},"excerpt":{"rendered":"

The treatment paradigm for advanced non-small cell lung cancer (NSCLC) has been fundamentally changed by the introduction of targeted therapies and immunotherapy over the past decade. Given that lung cancer remains a leading cause of global cancer mortality, understanding the regional molecular epidemiology is vital. This systematic review and expert opinion study aimed to determine …<\/p>\n","protected":false},"author":1,"featured_media":40070,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[39],"tags":[],"class_list":["post-40069","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cancers"],"acf":[],"aioseo_notices":[],"aioseo_head":"\n\t\t\n\t\n\t\n\t\n\t\n\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t